LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 32 of 67
Next
>>
>
776 to 800 of 1656 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Etoposide	180622_BG_6	850	0.1701	132	35	4	19	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_2	167	0.1642	832.0	168.3	20016	537.9	0.0261	0.13808	0.0047
Etoposide	180622_BG_6	906	0.1609	113	51	8	20	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_3	164	0.1533	832.0	168.3	20016	537.9	0.0261	0.12715	0.0187
Etoposide	180622_BG_7	878	0.1488	90	54	6	8	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_4	144	0.1409	832.0	168.3	20016	537.9	0.0261	0.11478	0.0118
Etoposide	180622_BG_7	751	0.1729	76	67	14	4	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_5	143	0.1600	832.0	168.3	20016	537.9	0.0261	0.13383	-0.0221
Etoposide	180622_BG_7	952	0.1386	80	63	14	17	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_6	143	0.1306	832.0	168.3	20016	537.9	0.0261	0.10447	0.0298
Etoposide	180622_BG_8	784	0.1895	92	74	4	3	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_7	166	0.1747	832.0	168.3	20016	537.9	0.0261	0.14861	-0.0129
Etoposide	180622_BG_8	803	0.1612	84	59	8	10	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_8	143	0.1512	832.0	168.3	20016	537.9	0.0261	0.12504	-0.0077
Etoposide	180622_BG_8	749	0.1814	78	72	12	4	Etoposide	3.193598006	treatment	72	2	MCF10A-GM_9	150	0.1669	832.0	168.3	20016	537.9	0.0261	0.14073	-0.0226
Etoposide	180622_BG_6	813	0.1957	153	36	4	15	Etoposide	9.98	treatment	72	2	MCF10A-GM_1	189	0.1886	832.0	168.3	20016	537.9	0.0261	0.16250	-0.0050
Etoposide	180622_BG_6	559	0.2760	162	37	6	22	Etoposide	9.98	treatment	72	2	MCF10A-GM_2	199	0.2625	832.0	168.3	20016	537.9	0.0261	0.23641	-0.0830
Etoposide	180622_BG_6	905	0.1403	93	47	10	7	Etoposide	9.98	treatment	72	2	MCF10A-GM_3	140	0.1340	832.0	168.3	20016	537.9	0.0261	0.10785	0.0185
Etoposide	180622_BG_7	875	0.1501	91	54	4	13	Etoposide	9.98	treatment	72	2	MCF10A-GM_4	145	0.1422	832.0	168.3	20016	537.9	0.0261	0.11603	0.0110
Etoposide	180622_BG_7	931	0.1708	129	52	7	17	Etoposide	9.98	treatment	72	2	MCF10A-GM_5	181	0.1628	832.0	168.3	20016	537.9	0.0261	0.13664	0.0248
Etoposide	180622_BG_7	896	0.1452	82	60	14	16	Etoposide	9.98	treatment	72	2	MCF10A-GM_6	142	0.1368	832.0	168.3	20016	537.9	0.0261	0.11068	0.0163
Etoposide	180622_BG_8	959	0.1466	71	80	9	8	Etoposide	9.98	treatment	72	2	MCF10A-GM_7	151	0.1360	832.0	168.3	20016	537.9	0.0261	0.10991	0.0314
Etoposide	180622_BG_8	859	0.1684	127	39	13	7	Etoposide	9.98	treatment	72	2	MCF10A-GM_8	166	0.1620	832.0	168.3	20016	537.9	0.0261	0.13583	0.0070
Etoposide	180622_BG_8	866	0.1589	84	67	13	12	Etoposide	9.98	treatment	72	2	MCF10A-GM_9	151	0.1485	832.0	168.3	20016	537.9	0.0261	0.12235	0.0088
Neratinib	180622_BG_6	20626	0.0316	100	554	3	13	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_1	654	0.0307	832.0	168.3	20016	537.9	0.0261	0.00461	1.0131
Neratinib	180622_BG_6	19446	0.0287	120	442	8	22	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_2	562	0.0281	832.0	168.3	20016	537.9	0.0261	0.00196	0.9874
Neratinib	180622_BG_6	20545	0.0246	100	407	11	17	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_3	507	0.0241	832.0	168.3	20016	537.9	0.0261	-0.00204	1.0114
Neratinib	180622_BG_7	20452	0.0276	54	511	3	17	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_4	565	0.0269	832.0	168.3	20016	537.9	0.0261	0.00076	1.0094
Neratinib	180622_BG_7	20877	0.0241	47	458	14	10	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_5	505	0.0236	832.0	168.3	20016	537.9	0.0261	-0.00251	1.0184
Neratinib	180622_BG_7	20361	0.0242	52	441	14	11	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_6	493	0.0236	832.0	168.3	20016	537.9	0.0261	-0.00248	1.0075
Neratinib	180622_BG_8	20652	0.0309	54	586	4	5	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_7	640	0.0301	832.0	168.3	20016	537.9	0.0261	0.00393	1.0137
Neratinib	180622_BG_8	21170	0.0268	56	513	11	22	Neratinib	0.001081167	treatment	72	2	MCF10A-GM_8	569	0.0262	832.0	168.3	20016	537.9	0.0261	0.00005	1.0246

|<
<<
Previous
Page 32 of 67
Next
>>
>
776 to 800 of 1656 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)